Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10898584 Modified RNA with decreased immunostimulatory properties

Patent 10898584 was granted and assigned to CureVac on January, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
CureVac
CureVac
Date Filed
April 29, 2016
Date of Patent
January 26, 2021
Patent Applicant
CureVac
CureVac
Patent Application Number
15142082
Patent Citations Received
‌
US Patent 12109275 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded protein
0
‌
US Patent 11865084 MERS coronavirus vaccine
0
‌
US Patent 11965000 Respiratory syncytial virus (RSV) vaccine
0
‌
US Patent 12083190 Rabies vaccine
0
‌
US Patent 11661634 Method for producing RNA
0
‌
US Patent 11667910 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
0
‌
US Patent 11760992 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
‌
US Patent 11761009 Artificial nucleic acid molecules for improved protein expression
‌
US Patent 11786590 Rotavirus vaccines
‌
US Patent 11834651 Method for producing and purifying RNA, comprising at least one step of tangential flow filtration
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10898584
Patent Primary Examiner
‌
Nancy J Leith

Find more entities like US Patent 10898584 Modified RNA with decreased immunostimulatory properties

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.